Use of aspirin associates with longer primary patency of hemodialysis grafts.

@article{Dixon2011UseOA,
  title={Use of aspirin associates with longer primary patency of hemodialysis grafts.},
  author={B. Dixon and G. Beck and L. Dember and M. Vazquez and A. Greenberg and J. Delmez and M. Allon and J. Himmelfarb and B. Hu and T. Greene and M. Radeva and I. Davidson and T. A. Ikizler and G. Braden and J. Lawson and J. Cotton and J. Kusek and H. Feldman},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2011},
  volume={22 4},
  pages={
          773-81
        }
}
  • B. Dixon, G. Beck, +15 authors H. Feldman
  • Published 2011
  • Medicine
  • Journal of the American Society of Nephrology : JASN
    • Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified… CONTINUE READING
    View PDF
    36 Citations
    Highly Influential Citations
    2
    Background Citations
    4
    Methods Citations
    1
    Results Citations
    1

    Figures, Tables, and Topics from this paper

    Figures and Tables

    Explore Further: Topics Discussed in This Paper

    36 Citations
    Citation Type

    Citation Type

    Role of antiplatelet therapy in the durability of hemodialysis access
    • 5
    Initiation of antiplatelet medication after surgical thrombectomy jeopardized arteriovenous graft longevity
    • 1
    The Effect of Aspirin on Preventing Vascular Access Dysfunction in Incident Hemodialysis Patients: A Prospective Cohort Study in Korean Clinical Research Centers for End-Stage Renal Disease (CRC for ESRD)
    • 1
    • PDF
    Association of Maturation Period Blood Pressure with Dialysis Access Patency
    • 7
    Combined use of heparin and anisodamine reduces the risk of early thrombosis in native arteriovenous fistula
    • 7
    Fish oil and hemodialysis graft patency: does time matter?
    Thrombophilia and arteriovenous fistula survival in ESRD.
    • 52
    • PDF
    Current Status of Synthetic and Biological Grafts for Hemodialysis
    • PDF
    Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review
    • 16
    Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
    • 1

    References

    SHOWING 1-10 OF 23 REFERENCES
    Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts.
    • 55
    Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study.
    • 187
    Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
    • 197
    • PDF
    Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis.
    • 33
    Design of the Dialysis Access Consortium (DAC) Aggrenox prevention of access stenosis trial
    • 29
    Vascular Access Outcomes and Medication Use: A USRDS Study
    • 55
    Clopidogrel Diminishes Hemodialysis Access Graft Thrombosis
    • 26
    Prevention of thrombosis in patients on hemodialysis by low-dose aspirin.
    • 229
    Natural history of arteriovenous grafts in hemodialysis patients.
    • 191
    Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    • 164